AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

numares Elects Kathy L. Bates as New Member of the Supervisory Board

September 10, 2019
1 of 2
numares Elects Kathy L. Bates as New Member of the Supervisory Board
1 of 2
numares Elects Kathy L. Bates as New Member of the Supervisory Board

REGENSBURG, Germany--(BUSINESS WIRE)--Sep 10, 2019--

numares appoints Kathy L. Bates, MBA, as new member of the Supervisory Board with immediate effect. Ms. Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, in Rochester, Minnesota.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005080/en/

Kathy L. Bates, MBA, Senior Director, Laboratory Services at Mayo Clinic (Photo: Mayo Clinic)

“We are delighted to welcome Kathy to the board,” says Dr. Volker Pfahlert, Chief Executive Officer of numares. “As we continue our focus on North American expansion, the depth of knowledge and relevant experience in the US healthcare will be invaluable to numares.” Ms. Bates is the first member of the Supervisory Board from the US. After starting her career in 1994, Ms. Bates completed various leading positions at Mayo Clinic and its partnership organizations. Her competence profile is supplemented by a large pool of experiences serving on the board of directors of Oncospire Genetics Inc. and on a Scientific Advisory Board for Roche Diagnostics Switzerland.

Since 2005 Kathy Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, leading technology evaluations and strategic business development activities in laboratory diagnostics.

Recently, numares and Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests using the “numares model” – meaning a distinctive nuclear magnetic resonance (NMR) technology, to identify metabolite constellations for diagnostics.

At the annual general meeting Ms. Bates was elected to follow Dr. Gerd Grenner, who supported numares as member of the Supervisory Board since 2014 and left his position due to private reasons. The other Board Members, Dr. Schirmers, Dr. Ries and Dr. Kutzner were reelected. Dr. Bernhard Schirmers, Chairman of the Supervisory Board, thanked Dr. Grenner in special recognition of his many years of commitment for his achievements on behalf of the Supervisory Board.

About numares

numares, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company’s AXINON ® system employs nuclear magnetic resonance (NMR) spectroscopy to create a spectrum standardized by Magnetic Group Signaling TM(MGS ® ) to evaluate metabolite constellations. MGS ® is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. More information: https://www.numares.com/.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005080/en/

CONTACT: numares

Julia Hertlein

Tel.: +49 941 280 949-14

E-Mail:julia.hertlein@numares.com

KEYWORD: GERMANY EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY PROFESSIONAL SERVICES HEALTH MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS FINANCE

SOURCE: numares

Copyright Business Wire 2019.

PUB: 09/10/2019 04:00 AM/DISC: 09/10/2019 04:00 AM

http://www.businesswire.com/news/home/20190910005080/en

All contents © copyright 2019 The Associated Press. All rights reserved.